This Week in HIV Research

Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.

Jan. 14, 2021: Interpersonal violence history and adverse HIV outcomes; the incidence and severity of breast cancer; the effect of menopause on integrase-associated weight gain; two-drug therapy for HIV treatment-experienced people.

Jan. 7, 2021: HIV status and COVID-19 disease severity; associations between tobacco smoking, cancer incidence, viral load, and CD4 count; immune recovery on integrase inhibitors; using smart pill bottles to boost adherence.

Dec. 17, 2020: HIV-related mortality in the U.S.; trends in extensive multidrug resistance; 96-week fostemsavir data; statins for microbial cancer prevention.

Dec. 10, 2020: Where the Ending the HIV Epidemic plan falls short; housing instability and HIV care incentives; financial wellbeing vs. health care access; San Diego's complex webs of HIV transmission.

Dec. 3, 2020: A simple scoring system for PrEP referral; integrating meth use and HIV prevention interventions; genetically linked HIV strains cross county lines; viral suppression rates in first vs. second pregnancies.

Nov. 19, 2020: Metformin's effect on weight and gut microbiota; integrase and cardiometabolics in women with HIV; ongoing link between HIV, smoking, and cancer; how early HIV treatment initiation impacts future cervical cancer outcomes.

Nov. 12, 2020: The most significant burdens experienced by PLWH; asymptomatic neurocognitive impairment and HAND risk; financial incentives for improving HIV knowledge and testing; linking HIV and COVID-19 testing.

Nov. 5, 2020: Success of direct referrals at re-linking people to HIV care; stable housing = viral suppression; modern-day rates of virologic failure; how pharmacy type affects HIV treatment outcomes.

Oct. 29, 2020: Diabetes incidence on INSTIs vs. NNRTIs vs. protease inhibitors; can NRTIs fight diabetes?; from TDF to TAF in HIV/HBV-coinfected people; assessing neurocognitive impacts of older two-drug regimens.